$Esperion Therapeutics (ESPR.US)$Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry: 1. Unique Market Position in Statin Alternatives – Addressing Statin Intolerance: There are millions of statin...
$Esperion Therapeutics (ESPR.US)$$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
Report
Millaai
:
You're under duvet, are you looking for a successor everywhere
Growth Investor27
Millaai
:
The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
Detached House
Millaai
:
You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
This unique biotech$Esperion Therapeutics (ESPR.US)$Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
14
1
4
Report
10xStockPicks
OP
:
This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed. So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look. 1. Boeing (down 36.5%) Boeing$Boeing (BA.US)$has had a r...
Today,$Amgen (AMGN.US)$announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again). I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
The market again hit records Tuesday, reacting mostly positively toward incoming President-Elect Trump's comments overnight that he would put a 25% tariff on our neighbors in Canada and Mexico and 35% on Chinese goods, our three largest trading partners. According to Census Bureau data, there are price hikes in the goods on 41% of the U.S.'s total imports; there has been $1.6T trade so far in 2024. A blanket ...
$Amgen (AMGN.US)$A 20% weight loss reduction in one year is fantastic and healthy from a medical standpoint. A 5 foot 4 inches woman at 180 pounds would loss guaranteed 36 pounds over 1 year be down to a much healthier 144 pounds. This is impressive results. I don’t understand the selloff. The human body should lose weight in a healthy fashion. I don’t know what you guys are expecting . This is great news .
5
1
Report
Jeronimo99
:
Apparently not as good as the current 2, especially the side effects.
Amgen Stock Forum
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
According to Census Bureau data, there are price hikes in the goods on 41% of the U.S.'s total imports; there has been $1.6T trade so far in 2024. A blanket ...
No comment yet